Fibrogenesis in Kidney Transplantation: Potential Targets for Prevention and Therapy

Overview

Journal Transplantation

Specialty General Surgery

Date 2009 Nov 26

PMID 19935366

Citations 14

Authors

Arjang Djamali

Millie Samaniego

Affiliations

Soon will be listed here.

Abstract

Kidney allograft fibrosis results from a reactive process mediated by humoral and cellular events and the activation of transforming growth factor beta1. It is a process that involves both parenchymal and graft infiltrating cells and can lead to organ failure if injury persists or if the response to injury is excessive. In this review, we will address the role of preventive and therapeutic strategies that target kidney allograft fibrogenesis. We conclude that in addition to preventive strategies, therapies based on bone morphogenetic protein 7, hepatocyte growth factor, connective tissue growth factor, and pirfenidone have shown promising results in preclinical studies. Clinical trials are needed to examine the effect of these therapies on long-term outcomes.

Citing Articles

Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.

Bogacz A, Wolek M, Sienko J, Czerny B, Machalinski B, Olbromski P Sci Rep. 2021; 11(1):17531.

PMID: 34475433 PMC: 8413317. DOI: 10.1038/s41598-021-96457-7.

PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease.

Tomasini-Johansson B, Zbyszynski P, Toraason I, Peters D, Kwon G PLoS One. 2018; 13(10):e0205360.

PMID: 30356276 PMC: 6200241. DOI: 10.1371/journal.pone.0205360.

BMP7 regulates lung fibroblast proliferation in newborn rats with bronchopulmonary dysplasia.

Sun Y, Fu J, Xue X, Yang H, Wu L Mol Med Rep. 2018; 17(5):6277-6284.

PMID: 29512787 PMC: 5928605. DOI: 10.3892/mmr.2018.8692.

Role of endothelial-to-mesenchymal transition induced by TGF-β1 in transplant kidney interstitial fibrosis.

Wang Z, Han Z, Tao J, Wang J, Liu X, Zhou W J Cell Mol Med. 2017; 21(10):2359-2369.

PMID: 28374926 PMC: 5618680. DOI: 10.1111/jcmm.13157.

Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation.

Li X, Zhuang S Fibrogenesis Tissue Repair. 2014; 7:15.

PMID: 25285155 PMC: 4185272. DOI: 10.1186/1755-1536-7-15.

References

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer W, Curhan G . Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006; 17(3):889-99. DOI: 10.1681/ASN.2005090955. View

Luo G, Lu Y, Song J, Yang L, Shi Y, Li Y . Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc. 2008; 40(7):2365-9. DOI: 10.1016/j.transproceed.2008.07.100. View

Shull M, Ormsby I, Kier A, Pawlowski S, Diebold R, Yin M . Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992; 359(6397):693-9. PMC: 3889166. DOI: 10.1038/359693a0. View

Grande M, Lopez-Novoa J . Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol. 2009; 5(6):319-28. DOI: 10.1038/nrneph.2009.74. View

Nickenig G, Harrison D . The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation. 2002; 105(3):393-6. DOI: 10.1161/hc0302.102618. View

Mannon R, Kopp J, Ruiz P, Griffiths R, Bustos M, Platt J . Chronic rejection of mouse kidney allografts. Kidney Int. 1999; 55(5):1935-44. DOI: 10.1046/j.1523-1755.1999.00423.x. View

Shihab F, Bennett W, Yi H, Andoh T . Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant. 2002; 2(2):111-9. DOI: 10.1034/j.1600-6143.2002.020201.x. View

Hsu W, Wang J . The use of bone morphogenetic protein in spine fusion. Spine J. 2008; 8(3):419-25. DOI: 10.1016/j.spinee.2008.01.008. View

Herrero-Fresneda I, Torras J, Franquesa M, Vidal A, Cruzado J, Lloberas N . HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int. 2006; 70(2):265-74. DOI: 10.1038/sj.ki.5001510. View

10.

Zavadil J, Bottinger E . TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24(37):5764-74. DOI: 10.1038/sj.onc.1208927. View

11.

Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N . A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol. 2007; 192(3):595-603. DOI: 10.1677/JOE-06-0045. View

12.

Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

13.

Mulay A, Hussain N, Fergusson D, Knoll G . Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant. 2005; 5(7):1748-56. DOI: 10.1111/j.1600-6143.2005.00931.x. View

14.

Nakagawa T . Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol. 2007; 292(6):F1665-72. DOI: 10.1152/ajprenal.00495.2006. View

15.

Burnier M, Zanchi A . Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2005; 24(1):11-25. DOI: 10.1097/01.hjh.0000191244.91314.9d. View

16.

Pollak R, Andrisevic J, Maddux M, Gruber S, Paller M . A randomized double-blind trial of the use of human recombinant superoxide dismutase in renal transplantation. Transplantation. 1993; 55(1):57-60. DOI: 10.1097/00007890-199301000-00011. View

17.

Liu H, Drew P, Gaugler A, Cheng Y, Visner G . Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant. 2005; 5(6):1256-63. DOI: 10.1111/j.1600-6143.2005.00876.x. View

18.

Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G . Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353(8):770-81. DOI: 10.1056/NEJMoa050085. View

19.

Albrecht E, Goor H, Smit-van Oosten A, Stegeman C . Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. Nitric Oxide. 2003; 8(1):53-8. DOI: 10.1016/s1089-8603(02)00132-5. View

20.

Longo R, Gasparini G . Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev Mol Diagn. 2008; 8(3):301-14. DOI: 10.1586/14737159.8.3.301. View